Methcathinone
Standing risks
| Risk | Recorded values | Confidence | Article section |
|---|---|---|---|
| Compulsive use risk, monitor frequency |
| medium | View in article: Compulsive use risk, monitor frequency |
| High dependence, taper carefully |
| medium | View in article: High dependence, taper carefully |
| Chronic toxicity, limit exposure |
| medium | View in article: Chronic toxicity, limit exposure |
Lethal interactions
| Combination | Type | Severity | Mechanisms | Confidence |
|---|---|---|---|---|
| MAOIs | Drug class | lethal | 6 | high |
Dangerous interactions
33 dangerous interactions recorded for this substance.
See the full interactions tableContraindications
| Condition | Severity | Note |
|---|---|---|
| Cardiovascular | ||
| severe cardiovascular disease | absolute | Methcathinone's sympathomimetic effects impose acute cardiovascular stress through norepinephrine-mediated vasoconstriction and cardiac stimulation. Individuals with severe cardiovascular disease, uncontrolled hypertension, or cardiac arrhythmia face elevated risk of adverse cardiovascular events. |
| long QT syndrome | absolute | Long QT syndrome is an absolute contraindication due to the combination of sympathomimetic cardiac stress and potential arrhythmia risk. |
| Psychiatric | ||
| psychotic disorders | absolute | History of psychosis or schizophrenia is an absolute contraindication. Methcathinone's potent dopamine-releasing activity poses high risk of precipitating acute psychotic episodes. Paranoia and hallucinations are documented adverse effects even in individuals without psychiatric history. |
| bipolar disorder | relative | Bipolar disorder is a relative contraindication. Methcathinone's catecholaminergic activity may precipitate manic episodes. The compulsive redosing pattern further increases risk of prolonged stimulant exposure leading to psychiatric destabilization. |
| Pregnancy & Breastfeeding | ||
| pregnancy | absolute | Pregnancy is an absolute contraindication. No reproductive safety data exist for methcathinone. Class-level risk from sympathomimetic vasoconstrictive effects on placental blood flow, combined with unknown teratogenic potential. |
| Other | ||
| concurrent MAOI therapy | absolute | Concurrent use of monoamine oxidase inhibitors (MAOIs) with methcathinone is absolutely contraindicated. The combination of monoamine release (methcathinone) with prevented monoamine breakdown (MAOI) produces potentially fatal monoamine excess. |